表达马尔堡病毒囊膜糖蛋白GP重组新城疫病毒的构建及免疫原性评估  

Construction of a recombinant Newcastle disease virus expressing Marburg virus glycoprotein and evaluation of its safety and immunogenicity in mice

作　　者：胡旭乐[1] 温志远[1] 宋坤[1] 王喜军[1] 陈伟业[1] 葛金英[1] 步志高[1] 

机构地区：[1]中国农业科学院哈尔滨兽医研究所兽医生物技术国家重点实验室/农业部兽医公共卫生重点开放实验室,黑龙江哈尔滨150001

出　　处：《中国预防兽医学报》2014年第9期667-671,共5页Chinese Journal of Preventive Veterinary Medicine

基　　金："十二五"国家支撑计划课题(2013BAD12B05)

摘　　要：为研制安全、有效的抗马尔堡病毒(MARV)疫苗,本研究将人工合成的MARV GP基因利用新城疫病毒LaSota疫苗株反向遗传操作系统构建并拯救得到表达MARV糖蛋白GP的重组病毒(rLa-MARVGP),并以小鼠为动物模型对其安全性和免疫原性进行评价。Western blot和间接免疫荧光试验表明MARV GP能够正确表达,其分子量为130 ku;动物实验结果表明rLa-MARVGP对小鼠高度安全;rLa-MARVGP免疫小鼠能够诱导产生抗MARV GP囊膜嵌合水疱性口炎病毒假病毒的特异性中和抗体。本研究表明rLa-MARVGP作为防控MARV的储备性疫苗具有潜在的应用价值。Marburg virus （MARV）, a member of the Filoviridae family, is a zoonotic pathogen that causes deadly Marburg hemorrhagic fever （MHF） in human and nonhuman primates. To develop a safe and effective candidate vaccine against MHF, we generated a recombinant Newcastle disease virus （NDV） of LaSota vaccine strain expressing the MARV glycoprotein （GP） by reverse genetics, designated rLa-MARVGP. The expression of MARV GP was confirmed by western blot and indirect immuno- fluorescence assay. Animal experiment showed rLa-MARVGP was highly safe for mouse. Immunization assay demonstrated the rLa-MARVGP was able to induce specific neutralizing antibodies in mice against pseudotyped VSVAG＊GFP-MARV-GP. Our data thus indicate rLa-MARVGP has the potential to be used as the vaccine candidate against MARV infection.

关 键 词：马尔堡病毒 囊膜糖蛋白 重组新城疫病毒 

分 类 号：S852.65[农业科学—基础兽医学]